Literature DB >> 2692922

Dysfunctional uterine bleeding.

I T Cameron.   

Abstract

The diagnosis of DUB is made by the exclusion of organic disease as a cause of the abnormal menses; the condition accounts for about 80% of cases of menorrhagia. Of these, over 80% will have no abnormality of the hypothalamo-pituitary-ovarian axis, and it is likely that the disorder is the result of local endometrial factors. There appears to be not only a preponderance of vasodilatory prostaglandins in the endometrium of women with menorrhagia, but also an excessive increase in fibrinolytic activity within the uterine cavity. Once a diagnosis has been reached with the aid of history, examination, haematological and endocrine investigations, and dilatation and curettage when appropriate, medical treatment is the usual first line approach. Non-steroidal anti-inflammatory drugs such as mefenamic acid, or antifibrinolytic agents such as tranexamic or epsilon aminocaproic acids, will reduce blood loss by between 25 and 50%. Though the former drugs are relatively free from side-effects in healthy women, intracranial thrombosis has been reported with the latter (Agnelli et al, 1982). Medications which suppress ovarian function, such as danazol or gonadotrophin releasing hormone analogues, are highly effective in lessening, or inhibiting, menstrual loss, but at the expense of side-effects and convenience respectively. The combined contraceptive pill may reduce blood loss by 50% but is not appropriate for older women. Cyclical gestagens such as norethisterone have been widely employed, particularly for the treatment of anovulatory cycles, but their place in the management of ovulatory DUB is less clear. If medical treatment fails hysterectomy should be considered, though less invasive surgical methods of endometrial ablation are being developed. Finally, it should be remembered that in the absence of associated signs or symptoms of iron-deficiency anaemia, heavy menstrual bleeding is a subjective complaint and up to 50% of women describing menorrhagia will have a measured monthly blood loss within normal limits.

Entities:  

Mesh:

Year:  1989        PMID: 2692922     DOI: 10.1016/s0950-3552(89)80024-0

Source DB:  PubMed          Journal:  Baillieres Clin Obstet Gynaecol        ISSN: 0950-3552


  8 in total

Review 1.  Managing menorrhagia.

Authors:  A Coulter; A Long; J Kelland; S O'Meara; M Sculpher; F Song; T A Sheldon
Journal:  Qual Health Care       Date:  1995-09

2.  A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia.

Authors:  M Bonduelle; J J Walker; A A Calder
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

3.  Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding.

Authors:  Magdalena Bofill Rodriguez; Anne Lethaby; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2019-09-19

4.  Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study.

Authors:  G R Fender; A Prentice; T Gorst; R M Nixon; S W Duffy; N E Day; S K Smith
Journal:  BMJ       Date:  1999-05-08

Review 5.  Tranexamic acid: a review of its use in the management of menorrhagia.

Authors:  Keri Wellington; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Danazol for heavy menstrual bleeding.

Authors:  H Beaumont; C Augood; K Duckitt; A Lethaby
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

7.  Screening bleeding disorders in adolescents and young women with menorrhagia.

Authors:  Suar Cakı Kılıç; Nazan Sarper; Emine Zengin; Sema Aylan Gelen
Journal:  Turk J Haematol       Date:  2013-06-05       Impact factor: 1.831

8.  Progestogen-releasing intrauterine systems for heavy menstrual bleeding.

Authors:  Magdalena Bofill Rodriguez; Anne Lethaby; Vanessa Jordan
Journal:  Cochrane Database Syst Rev       Date:  2020-06-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.